Editor's note

This ExpertREACT article was originally published on 2 November 2010. Financial results and market positions described reflect the state of knowledge at that date.

Strong Q3 driven by seasonal influenza

According to VacZine Analytics' analysis, the major vaccine players sold approximately $5.7bn in Q3 2010, an increase on the $4.6bn figure calculated for Q2. Seasonal influenza vaccines accounted for approximately $1.2bn of Q3 revenues as major suppliers shipped ahead of a predicted record US flu season. GSK Biologicals sold $1.5bn (£982m) of vaccines in Q3, reporting strong growth in the USA (+32%), Emerging Markets (+29%) and Asia Pacific/Japan (greater than 100%). Synflorix, GSK's 10-valent pneumococcal vaccine, recorded £90m in Q3 alone - exceeding its entire H1 2010 figure of £83m - following a significant long-term contract win with the Brazilian government. Synflorix was by then approved in 71 countries.

GSK's bivalent HPV vaccine Cervarix grew 64% in Q3 to register £48m, of which £19m was from Japan. GSK stated that Cervarix was winning over half of competitive tenders globally and was on track to beat 2009 sales of £187m. However, Rotarix sales remained down 40% due to the PCV-1 contamination episode earlier in the year, with the development of a PCV-1-free formulation ongoing. A significant setback occurred in late September when GSK halted its Simplirix (herpes simplex) Phase III programme after the Herpevac trial showed no efficacy against its primary endpoint - a reminder that even well-advanced vaccine candidates can fail at late stages.

Q3 2010 top 5 vaccine sales
$5.7bn
Up from $4.6bn in Q2 2010; seasonal influenza vaccines contributed approximately $1.2bn ahead of a predicted record US flu season

Sanofi and Novartis positioning

Sanofi Pasteur sold approximately €1.2bn of vaccines in Q3 2010, boosted by seasonal influenza sales of €480m. Of these, Sanofi reported over 50% market share in the US market for the forthcoming influenza season, with 70m doses being shipped to US providers. Novartis Vaccines, meanwhile, was advancing its Menveo ACWY conjugate vaccine following recent US and EU approvals, with the company noting that infant (under 1 year) schedule recommendation would be required to truly replace lost H1N1 revenue. Novartis' MenB programme remained on track for EU submission.